Literature DB >> 25628933

Anti-miR21 oligonucleotide enhances chemosensitivity of T98G cell line to doxorubicin by inducing apoptosis.

Laura Giunti1, Martina da Ros2, Serena Vinci3, Stefania Gelmini3, Anna Lisa Iorio2, Anna Maria Buccoliero4, Stefania Cardellicchio2, Francesca Castiglione4, Lorenzo Genitori5, Maurizio de Martino6, Sabrina Giglio7, Maurizio Genuardi8, Iacopo Sardi2.   

Abstract

Various signal transduction pathways seem to be involved in chemoresistance mechanism of glioblastomas (GBMs). miR-21 is an important oncogenic miRNA which modulates drug resistance of tumor cells. We analyzed the expression of 5 miRNAs, previously found to be dysregulated in high grade gliomas, in 9 pediatric (pGBM) and in 5 adult (aGBM) GBMs. miR-21 was over-expressed, with a significant difference between pGBMs and aGBMs represented by a 4 times lower degree of expression in the pediatric compared to the adult series (p = 0.001). Doxorubicin (Dox) seems to be an effective anti-glioma agent with high antitumor activity also against glioblastoma stem cells. We therefore evaluated the chemosensitivity to Dox in 3 GBM cell lines (A172, U87MG and T98G). Dox had a cytotoxic effect after 48 h of treatment in A172 and U87MG, while T98G cells were resistant. TUNEL assay verified that Dox induced apoptosis in A172 and U87MG but not in T98G. miR-21 showed a low basal expression in treated cells and was over-expressed in untreated cells. To validate the possible association of miR-21 with drug resistance of T98G cells, we transfected anti-miR-21 inhibitor into the cells. The expression level of miR-21 was significantly lower in T98G transfected cells (than in the parental control cells). Transfected cells showed a high apoptotic rate compared to control after Dox treatment by TUNEL assay, suggesting that combined Dox and miR-21 inhibitor therapy can sensitize GBM resistant cells to anthracyclines by enhancing apoptosis.

Entities:  

Keywords:  CNS tumors; expression analysis; glioblastoma multiforme; miRNA; pediatric brain tumors

Year:  2014        PMID: 25628933      PMCID: PMC4300700     

Source DB:  PubMed          Journal:  Am J Cancer Res        ISSN: 2156-6976            Impact factor:   6.166


  45 in total

1.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method.

Authors:  K J Livak; T D Schmittgen
Journal:  Methods       Date:  2001-12       Impact factor: 3.608

2.  A microRNA array reveals extensive regulation of microRNAs during brain development.

Authors:  Anna M Krichevsky; Kevin S King; Christine P Donahue; Konstantin Khrapko; Kenneth S Kosik
Journal:  RNA       Date:  2003-10       Impact factor: 4.942

3.  MicroRNA-21 promotes the cell proliferation, invasion and migration abilities in ovarian epithelial carcinomas through inhibiting the expression of PTEN protein.

Authors:  Yanhui Lou; Xingsheng Yang; Fuling Wang; Zhumei Cui; Yu Huang
Journal:  Int J Mol Med       Date:  2010-12       Impact factor: 4.101

4.  Downregulation of miR-21 inhibits EGFR pathway and suppresses the growth of human glioblastoma cells independent of PTEN status.

Authors:  Xuan Zhou; Yu Ren; Lynette Moore; Mei Mei; Yongping You; Peng Xu; Baoli Wang; Guangxiu Wang; Zhifan Jia; Peiyu Pu; Wei Zhang; Chunsheng Kang
Journal:  Lab Invest       Date:  2010-01-04       Impact factor: 5.662

5.  Molecular cloning and expression analysis of a novel gene DGCR8 located in the DiGeorge syndrome chromosomal region.

Authors:  Aiko Shiohama; Takashi Sasaki; Setsuko Noda; Shinsei Minoshima; Nobuyoshi Shimizu
Journal:  Biochem Biophys Res Commun       Date:  2003-04-25       Impact factor: 3.575

6.  MicroRNA-21 inhibitor sensitizes human glioblastoma cells U251 (PTEN-mutant) and LN229 (PTEN-wild type) to taxol.

Authors:  Yu Ren; Xuan Zhou; Mei Mei; Xu-Bo Yuan; Lei Han; Guang-Xiu Wang; Zhi-Fan Jia; Peng Xu; Pei-Yu Pu; Chun-Sheng Kang
Journal:  BMC Cancer       Date:  2010-01-31       Impact factor: 4.430

Review 7.  Genetic pathways to primary and secondary glioblastoma.

Authors:  Hiroko Ohgaki; Paul Kleihues
Journal:  Am J Pathol       Date:  2007-05       Impact factor: 4.307

Review 8.  MiRNAs and cancer.

Authors:  Rosa Visone; Carlo M Croce
Journal:  Am J Pathol       Date:  2009-03-05       Impact factor: 4.307

9.  MicroRNA-21 down-regulates the expression of tumor suppressor PDCD4 in human glioblastoma cell T98G.

Authors:  Yang Chen; Wei Liu; Tengfei Chao; Yu Zhang; Xingqi Yan; Yanhua Gong; Boqin Qiang; Jiangang Yuan; Maosheng Sun; Xiaozhong Peng
Journal:  Cancer Lett       Date:  2008-11-13       Impact factor: 8.679

10.  MicroRNA-21 directly targets MARCKS and promotes apoptosis resistance and invasion in prostate cancer cells.

Authors:  Tao Li; Dong Li; Jianjun Sha; Peng Sun; Yiran Huang
Journal:  Biochem Biophys Res Commun       Date:  2009-03-18       Impact factor: 3.575

View more
  21 in total

1.  miR-21 is involved in transforming growth factor β1-induced chemoresistance and invasion by targeting PTEN in breast cancer.

Authors:  Xiaomeng Dai; Mao Fang; Shuang Li; Yongrong Yan; Ying Zhong; Bin Du
Journal:  Oncol Lett       Date:  2017-09-20       Impact factor: 2.967

2.  Na/K-ATPase signaling regulates collagen synthesis through microRNA-29b-3p in cardiac fibroblasts.

Authors:  Christopher A Drummond; Michael C Hill; Huilin Shi; Xiaoming Fan; Jeffrey X Xie; Steven T Haller; David J Kennedy; Jiang Liu; Michael R Garrett; Zijian Xie; Christopher J Cooper; Joseph I Shapiro; Jiang Tian
Journal:  Physiol Genomics       Date:  2015-12-23       Impact factor: 3.107

3.  Long noncoding RNA CNALPTC1 promotes cell proliferation and migration of papillary thyroid cancer via sponging miR-30 family.

Authors:  Cunrong Chen; Lili Zhou; Hui Wang; Junnian Chen; Wen Li; Wei Liu; Mingjie Shen; Hongzhou Liu; Xiaomin Fu
Journal:  Am J Cancer Res       Date:  2018-01-01       Impact factor: 6.166

Review 4.  MiR-21: an environmental driver of malignant melanoma?

Authors:  Bodo C Melnik
Journal:  J Transl Med       Date:  2015-06-27       Impact factor: 5.531

Review 5.  Role of MicroRNAs in Malignant Glioma.

Authors:  Bao-Cheng Wang; Jie Ma
Journal:  Chin Med J (Engl)       Date:  2015-05-05       Impact factor: 2.628

Review 6.  Targeting oncomiRNAs and mimicking tumor suppressor miRNAs: Νew trends in the development of miRNA therapeutic strategies in oncology (Review).

Authors:  Roberto Gambari; Eleonora Brognara; Demetrios A Spandidos; Enrica Fabbri
Journal:  Int J Oncol       Date:  2016-05-04       Impact factor: 5.650

7.  Inflammatory cytokine IL6 cooperates with CUDR to aggravate hepatocyte-like stem cells malignant transformation through NF-κB signaling.

Authors:  Qidi Zheng; Zhuojia Lin; Xiaonan Li; Xiaoru Xin; Mengying Wu; Jiahui An; Xin Gui; Tianming Li; Hu Pu; Haiyan Li; Dongdong Lu
Journal:  Sci Rep       Date:  2016-11-11       Impact factor: 4.379

Review 8.  Influence of microRNAs and Long Non-Coding RNAs in Cancer Chemoresistance.

Authors:  Duncan Ayers; Jo Vandesompele
Journal:  Genes (Basel)       Date:  2017-03-03       Impact factor: 4.096

9.  MicroRNA-21 Increases Proliferation and Cisplatin Sensitivity of Osteosarcoma-Derived Cells.

Authors:  Vanita Vanas; Barbara Haigl; Verena Stockhammer; Hedwig Sutterlüty-Fall
Journal:  PLoS One       Date:  2016-08-11       Impact factor: 3.240

Review 10.  MicroRNAs in glioblastoma multiforme pathogenesis and therapeutics.

Authors:  Amanda Shea; Varsha Harish; Zainab Afzal; Juliet Chijioke; Habib Kedir; Shahnoza Dusmatova; Arpita Roy; Malathi Ramalinga; Brent Harris; Jan Blancato; Mukesh Verma; Deepak Kumar
Journal:  Cancer Med       Date:  2016-06-10       Impact factor: 4.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.